Market overview
The global bioabsorbable stents market is worth USD 92 mn in 2026 and is forecast to reach USD 181 mn by 2036, growing at a 7.0% CAGR. Germany is the largest country market and Magnesium alloy scaffolds is the largest by material segment.
| Scope | Coronary and peripheral stents that dissolve in the body over months to years, including magnesium alloy and polylactic acid scaffolds, sold to cath labs. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 85 mn |
| Value 2026 | USD 92 mn |
| Value 2036 | USD 181 mn |
| CAGR 2026-2036 | 7.0% |
| Volume 2026 | 59.1 thousand units |
| Volume 2036 | 111 thousand units |
| Average price 2026 | USD 1,553 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Bioabsorbable Stents market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 92 mn |
| 2027 | USD 98 mn |
| 2028 | USD 105 mn |
| 2029 | USD 112 mn |
| 2030 | USD 120 mn |
| 2031 | USD 129 mn |
| 2032 | USD 138 mn |
| 2033 | USD 147 mn |
| 2034 | USD 158 mn |
| 2035 | USD 169 mn |
| 2036 | USD 181 mn |
Bioabsorbable Stents market segmentation
By material
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Magnesium alloy scaffolds | 52.0% | 59.7% | USD 48 mn | 8.5% |
| Polylactic acid scaffolds | 36.0% | 28.4% | USD 33 mn | 4.5% |
| Other resorbable scaffolds | 12.0% | 12.0% | USD 11 mn | 7.0% |
By application
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Coronary | 58.0% | 51.1% | USD 53 mn | 5.7% |
| Peripheral and below-the-knee | 30.0% | 34.9% | USD 28 mn | 8.6% |
| Paediatric and other | 12.0% | 14.0% | USD 11 mn | 8.6% |
By coating
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Drug eluting | 52.0% | 50.0% | USD 48 mn | 6.6% |
| Polymer coated | 20.0% | 20.0% | USD 18 mn | 7.0% |
| Bare scaffold | 28.0% | 30.0% | USD 26 mn | 7.7% |
By scaffold polymer
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Poly-L-lactic acid | 52.0% | 46.0% | USD 48 mn | 5.7% |
| Magnesium alloy | 24.0% | 30.0% | USD 22 mn | 9.4% |
| Polycarbonate derivatives | 14.0% | 14.0% | USD 13 mn | 7.0% |
| Salicylate polymers | 10.0% | 10.0% | USD 9.2 mn | 7.0% |
By vessel
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Coronary | 78.0% | 74.0% | USD 72 mn | 6.4% |
| Peripheral | 14.0% | 16.0% | USD 13 mn | 8.4% |
| Below the knee | 8.0% | 10.0% | USD 7.3 mn | 9.4% |
Top 25 countries for bioabsorbable stents by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 72.0% of 2026 revenue and the 25 countries below together hold 92.7%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | Germany | USD 13 mn | 14.0% | USD 23 mn | 6.1% |
| 2 | Japan | USD 10 mn | 11.0% | USD 18 mn | 5.7% |
| 3 | India | USD 8.3 mn | 9.0% | USD 22 mn | 10.2% |
| 4 | Italy | USD 7.3 mn | 8.0% | USD 13 mn | 5.7% |
| 5 | France | USD 6.4 mn | 7.0% | USD 12 mn | 6.2% |
| 6 | Spain | USD 5.5 mn | 6.0% | USD 9.9 mn | 6.1% |
| 7 | United Kingdom | USD 4.6 mn | 5.0% | USD 8.7 mn | 6.6% |
| 8 | Brazil | USD 4.6 mn | 5.0% | USD 10 mn | 8.2% |
| 9 | Turkey | USD 3.7 mn | 4.0% | USD 8.1 mn | 8.3% |
| 10 | Netherlands | USD 2.8 mn | 3.0% | USD 5.2 mn | 6.6% |
| 11 | South Korea | USD 2.7 mn | 2.9% | USD 5.8 mn | 8.0% |
| 12 | Belgium | USD 2.2 mn | 2.4% | USD 4.2 mn | 6.8% |
| 13 | Switzerland | USD 1.9 mn | 2.1% | USD 3.7 mn | 6.8% |
| 14 | Austria | USD 1.8 mn | 1.9% | USD 3.4 mn | 6.8% |
| 15 | Poland | USD 1.7 mn | 1.8% | USD 3.6 mn | 8.1% |
| 16 | Israel | USD 1.7 mn | 1.8% | USD 3.2 mn | 6.8% |
| 17 | Portugal | USD 1.2 mn | 1.4% | USD 2.4 mn | 6.8% |
| 18 | Mexico | USD 1.0 mn | 1.1% | USD 2.2 mn | 8.0% |
| 19 | Russia | USD 0.93 mn | 1.0% | USD 2.0 mn | 8.0% |
| 20 | China | USD 0.89 mn | 1.0% | USD 1.7 mn | 6.8% |
| 21 | Saudi Arabia | USD 0.87 mn | 0.9% | USD 1.9 mn | 8.1% |
| 22 | Czech Republic | USD 0.66 mn | 0.7% | USD 1.3 mn | 6.7% |
| 23 | Argentina | USD 0.63 mn | 0.7% | USD 1.4 mn | 7.9% |
| 24 | Greece | USD 0.51 mn | 0.6% | USD 0.99 mn | 6.8% |
| 25 | Australia | USD 0.41 mn | 0.5% | USD 0.79 mn | 6.8% |
| Rest of world | USD 6.7 mn | 7.3% | USD 13 mn | 6.7% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Biotronik
Group 2: Regional and specialist players
- Elixir Medical
- Meril Life Sciences
- MicroPort
- Kyoto Medical Planning
- Huaan Biotech
- Arterial Remodeling Technologies
Group 3: Emerging and niche players
- Lepu Medical
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the bioabsorbable stents market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 7.0% is calculated from the resulting values.
The market is divided by material, by application, by coating, by scaffold polymer, by vessel. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the bioabsorbable stents market?
The global bioabsorbable stents market is estimated at USD 85 mn in 2025 and USD 92 mn in 2026.
How fast will the bioabsorbable stents market grow?
It is forecast to reach USD 181 mn by 2036, a compound annual growth rate of 7.0% from 2026, an increase of USD 89 mn.
Which country is the largest market for bioabsorbable stents?
Germany is the largest market by revenue at USD 13 mn in 2026, 14.0% of the global total. The three largest countries together hold 34.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 10.2% a year from 2026 to 2036.
Which bioabsorbable stents segment is largest?
In the by material split, Magnesium alloy scaffolds is the largest segment with 52.0% of 2026 revenue.
Who are the leading bioabsorbable stents companies?
Global leaders include Biotronik.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Aquaculture Fungal Infection TreatmentUSD 90 mn · 6.0% CAGR
- Ostomy Irrigation ProductsUSD 94 mn · 4.3% CAGR
- Brachytherapy Treatment Planning SystemsUSD 95 mn · 5.8% CAGR
- Lacrimal DevicesUSD 87 mn · 5.0% CAGR
- Breast Cancer Grading ToolsUSD 102 mn · 17.0% CAGR
- Vaccine CryoprotectantsUSD 81 mn · 8.0% CAGR
- Federated Learning Drug DiscoveryUSD 104 mn · 20.0% CAGR
- Federated Learning HealthcareUSD 78 mn · 22.0% CAGR